Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 4/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.38 |
| ▸ | STK16 | O75716 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.38 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13574110 | 0.91 | MAP4K1 (0.46) | MAP4K1SYKACVR1CDK1KDR | |
| SCHEMBL13363225 | 0.90 | MAP4K1 (0.45) | MAP4K1SYKACVR1CDK1KDR | |
| SCHEMBL13336335 | 0.88 | MAP4K1 (0.43) | MAP4K1SYKACVR1CDK1KDR | |
| SCHEMBL13335985 | 0.85 | SYK (0.49) | SYKACVR1CDK1KDRTYK2 | |
| SCHEMBL1571422 | 0.83 | JUN (0.46) | MAP4K1SYKCDK1KDRIGF1R | |
| SCHEMBL13336100 | 0.82 | SYK (0.47) | MAP4K1SYKCDK1KDRJUN | |
| SCHEMBL13335988 | 0.82 | SYK (0.47) | SYKCDK1KDRMAPK10TYK2 | |
| SCHEMBL13336028 | 0.82 | MAP4K1 (0.43) | MAP4K1SYKJUNMAPK8MAPK9 | |
| SCHEMBL13336326 | 0.82 | SYK (0.50) | SYKACVR1CDK1KDRTYK2 | |
| SCHEMBL13336192 | 0.81 | MAP4K1 (0.43) | MAP4K1SYKKDRJUNMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | MAP4K1 112/4885SYK 4070/4885ACVR1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.